Irvine-based eye device maker AqueSys Inc. said today that it has raised $43.6 million in a fourth round of funding.
AqueSys plans to use the money to “accelerate the execution and attainment of our clinical, regulatory and commercial goals.”
The company is developing an implant for treating glaucoma, an eye disease that damages the optic nerve and is a major cause of blindness.
Investors in the round include Washington, D.C.-based Carlyle Group, Longitude Capital of Menlo Park and Greenwich, Conn., as well as Rho Ventures, which has offices in New York, Menlo Park and Montreal.
There were other undisclosed investors.
AqueSys was founded in 2006.
